Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy
Ujjwol Khatri(University of Oklahoma Health Sciences Center), Jie Wu(University of Oklahoma Health Sciences Center)
Cited by 1
Related Papers
Phosphotyrosines 627 and 659 of Gab1 Constitute a Bisphosphoryl Tyrosine-based Activation Motif (BTAM) Conferring Binding and Activation of SHP2
|Journal of Biological Chemistry|2001|167
Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma
|British Journal of Cancer|2015|81
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
|npj Precision Oncology|2021|49
PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
|Molecular Medicine Reports|2018|17
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
|Molecular Cancer Therapeutics|2023|14